CN115836070A - 作为egfr抑制剂的稠环化合物及其制备方法和应用 - Google Patents

作为egfr抑制剂的稠环化合物及其制备方法和应用 Download PDF

Info

Publication number
CN115836070A
CN115836070A CN202180048447.4A CN202180048447A CN115836070A CN 115836070 A CN115836070 A CN 115836070A CN 202180048447 A CN202180048447 A CN 202180048447A CN 115836070 A CN115836070 A CN 115836070A
Authority
CN
China
Prior art keywords
alkyl
substituted
radical
deuterium
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180048447.4A
Other languages
English (en)
Other versions
CN115836070B (zh
Inventor
寻国良
喻红平
陈椎
徐耀昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbisko Therapeutics Co Ltd
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of CN115836070A publication Critical patent/CN115836070A/zh
Application granted granted Critical
Publication of CN115836070B publication Critical patent/CN115836070B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

作为EGFR抑制剂的式(I)结构稠环化合物、其制备方法、含有其的药物组合物以及其在治疗和/或预防至少部分由与EGFR外显子20插入或缺失突变相关的癌症、肿瘤或转移性疾病中的用途，特别是在治疗过度增殖性疾病和诱导细胞死亡障碍疾病中的用途。其中式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180048447.4A 2020-08-10 2021-08-09 作为egfr抑制剂的稠环化合物及其制备方法和应用 Active CN115836070B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010794193 2020-08-10
CN2020107941938 2020-08-10
PCT/CN2021/111447 WO2022033416A1 (zh) 2020-08-10 2021-08-09 作为egfr抑制剂的稠环化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115836070A true CN115836070A (zh) 2023-03-21
CN115836070B CN115836070B (zh) 2024-08-09

Family

ID=80246903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048447.4A Active CN115836070B (zh) 2020-08-10 2021-08-09 作为egfr抑制剂的稠环化合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN115836070B (zh)
WO (1) WO2022033416A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CA3246654A1 (en) * 2022-03-24 2023-09-28 Antares Therapeutics, Inc. METHODS FOR SYNTHESIZING EGFR INHIBITORS
US20250282795A1 (en) * 2022-04-20 2025-09-11 Celyn Therapeutics, Inc. EGFR Inhibitors in cancer treatment
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315285A (zh) * 2014-07-25 2016-02-10 上海海雁医药科技有限公司 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CN107406417A (zh) * 2015-01-28 2017-11-28 拜耳制药股份公司 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物
WO2019081486A1 (en) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CN109843858A (zh) * 2016-08-15 2019-06-04 润新生物公司 某些化学实体、组合物及方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
US20240307362A1 (en) * 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
DK3959211T3 (da) * 2019-04-24 2026-04-27 Bayer Ag 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315285A (zh) * 2014-07-25 2016-02-10 上海海雁医药科技有限公司 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CN107406417A (zh) * 2015-01-28 2017-11-28 拜耳制药股份公司 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物
CN109843858A (zh) * 2016-08-15 2019-06-04 润新生物公司 某些化学实体、组合物及方法
WO2019081486A1 (en) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHUNMEI LI等: "A multicomponent two-step strategy for the synthesis of polysubstituted pyrrolo[3, 2-c]pyridin- 4-ones using a solid acid as a recyclable catalyst", 《GREEN CHEMISTRY》, 8 May 2019 (2019-05-08), pages 3109 *

Also Published As

Publication number Publication date
WO2022033416A1 (zh) 2022-02-17
CN115836070B (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
CN115836070A (zh) 作为egfr抑制剂的稠环化合物及其制备方法和应用
CN116096372B (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
CN115803326B (zh) Egfr抑制剂及其制备方法与在药学上的应用
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
CN114874234A (zh) 作为kras g12c抑制剂的三环类化合物及其应用
CN115768757B (zh) Cd206调节剂及其用途和制备方法
WO2024125437A1 (zh) Gspt1降解剂及其应用
CN110483485A (zh) 嘧啶类化合物、其制备方法和医药用途
CN120418246A (zh) 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
US20260078121A1 (en) Inhibitors of enl/af9 yeats and flt3
CN115836064B (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
CN113861195B (zh) 一种多稠环egfr抑制剂及其制备方法和应用
ES3061587T3 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
CN110054613B (zh) 取代的氨基喹唑啉类化合物及其药物组合物及其用途
CN104418867B (zh) 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
WO2024148932A1 (zh) 一种egfr c797s突变抑制剂及其在药学上的应用
CN109111439A (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN115701429B (zh) 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用
CN116981662B (zh) 嘧啶-4,6-二胺衍生物及其制备方法和药学上的应用
CN115884776B (zh) 杂环大环化合物及其医药用途
CN118255713B (zh) 一种萘酰胺类化合物、其制备方法及其应用
CN119013283A (zh) 大环egfr抑制剂及其制备方法和药学上的应用
HK40104987A (zh) 氮杂芳基化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant